Drug Trial Radar · NCT01876771
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
413
Actual
Start
Apr 29, 2014
Primary completion
Dec 2042
Study completion Dec 2042
Sponsor
- Lead sponsor
- AHS Cancer Control AlbertaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 13, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is approved in Canada, it is not publicly funded in Alberta. Lu-DOTA-TATE has been used at the Cross Cancer Institute to treat more than 300 patients with NETs since August, 2010. Our Lu-DOTA-TATE treatment was initially given under Health Canada's Special Access Programme (SAP), with each individual treatment requiring separate approval. In 2014, Health Canada requested we conduct a clinical trial with Lu-DOTA-TATE instead. The purpose of this study is to: 1) assess the efficacy of Lu-DOTA-TATE treatment in patients with somatostatin receptor positive tumours; 2) assess the safety of Lu-DOTA-TATE; 3) assess the effect of Lu-DOTA-TATE on Quality of Life and survival.
Conditions
- Carcinoma, Neuroendocrine
Interventions
[177]Lu-DOTA-TATEDrug
Peptide receptor radionuclide therapy (PPRT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Tumour response of the target lesion(s) through end of treatmentTime frame: At screening, 12-20 weeks after each treatment cycle, and 6 months and 1 year after the last treatment
- Median progression-free survivalTime frame: Up to 1 year after last treatment
- Lu-177 scan disease evaluationTime frame: Up to 3 days after each Lu-DOTA-TATE treatment
- Change in tumour marker levelsTime frame: At baseline, 12-20 weeks after each treatment cycle, and 6 months and 1 year after last treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cross Cancer Institute
Edmonton, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.